---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024174"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:38:58.159820+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ProPhase Q3 net loss $6.8M, revenue down 36%; working capital deficit $47.5M

## Summary
- Q3 net loss from continuing ops $6.8M ($0.16/sh) vs $5.0M ($0.26/sh) prior year; revenue $0.9M down from $1.4M
- Cash $405K; working capital deficit $47.5M at Sep 30 vs $1.5M at Dec 31, 2024
- Crown Medical appointed Special Counsel to recover $50M+ net A/R; first settlement completed
- BE-Smart esophageal cancer test validated by Mayo Clinic; commercialization rollout underway
- Nebula Genomics pro-forma profitable; strategic M&A discussions ongoing

## SEC filing metadata
- accession: 0001493152-25-024174
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000149315225024174/0001493152-25-024174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000149315225024174/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024174
- JSON: https://secwatch.observer/filing/0001493152-25-024174.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.